Drug Information

Drug General Information
Drug ID
D0O2JI
Former ID
DIB001398
Drug Name
Ertumaxomab
Synonyms
Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius
Drug Type
Antibody
Indication Breast cancer [ICD9: 174, 175; ICD10:C50] Phase 2 [529707], [531972]
Advanced breast cancer [ICD9: 174, 175; ICD10:C50] Phase 1 [889343]
Company
Trion
CAS Number
CAS 509077-99-0
Target and Pathway
Target(s) CD3 Target Info [529707], [531972]
T-cell surface glycoprotein CD3 epsilon chain Target Info [529707], [531972]
Receptor protein-tyrosine kinase erbB-2 Target Info [529707], [531972]
KEGG Pathway Hematopoietic cell lineage
T cell receptor signaling pathway
Chagas disease (American trypanosomiasis)
Measles
HTLV-I infectionhsa04640:Hematopoietic cell lineage
HTLV-I infection
Primary immunodeficiencyhsa04012:ErbB signaling pathway
Calcium signaling pathway
HIF-1 signaling pathway
Focal adhesion
Adherens junction
Pathways in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Pancreatic cancer
Endometrial cancer
Prostate cancer
Bladder cancer
Non-small cell lung cancer
Central carbon metabolism in cancer
NetPath Pathway TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
Leptin Signaling PathwayNetPath_11:TCR Signaling Pathway
PANTHER Pathway T cell activationP00053:T cell activationP00012:Cadherin signaling pathway
EGF receptor signaling pathway
Pathway Interaction Database TCR signaling in na&#xef
IL12-mediated signaling events
TCR signaling in na&#xef
CXCR4-mediated signaling events
Downstream signaling in na&#xef
IL12 signaling mediated by STAT4tcr_pathway:TCR signaling in na&#xef
IL23-mediated signaling events
IL12 signaling mediated by STAT4erbb4_pathway:ErbB4 signaling events
ErbB2/ErbB3 signaling events
ErbB receptor signaling network
a6b1 and a6b4 Integrin signaling
Validated targets of C-MYC transcriptional repression
PathWhiz Pathway Phosphatidylinositol Phosphate Metabolism
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Phosphorylation of CD3 and TCR zeta chains
Translocation of ZAP-70 to Immunological synapse
Generation of second messenger molecules
FCGR activation
Regulation of actin dynamics for phagocytic cup formation
Role of phospholipids in phagocytosis
PD-1 signalingR-HSA-198933:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
PD-1 signalingR-HSA-1250196:SHC1 events in ERBB2 signaling
PLCG1 events in ERBB2 signaling
PIP3 activates AKT signaling
GRB2 events in ERBB2 signaling
PI3K events in ERBB2 signaling
Constitutive Signaling by Aberrant PI3K in Cancer
Sema4D induced cell migration and growth-cone collapse
RAF/MAP kinase cascade
WikiPathways TCR Signaling Pathway
Fcgamma receptor (FCGR) dependent phagocytosis
TCR signaling
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Costimulation by the CD28 familyWP69:TCR Signaling Pathway
Costimulation by the CD28 familyWP710:DNA Damage Response (only ATM dependent)
ErbB Signaling Pathway
EGF/EGFR Signaling Pathway
Focal Adhesion
Extracellular vesicle-mediated signaling in recipient cells
Bladder Cancer
Signaling by ERBB2
Integrated Pancreatic Cancer Pathway
Signaling Pathways in Glioblastoma
Leptin signaling pathway
miR-targeted genes in muscle cell - TarBase
Semaphorin interactions
References
Ref 529707Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8.
Ref 531972Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
Ref 889343ClinicalTrials.gov (NCT00452140) Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
Ref 529707Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8.
Ref 531972Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.